Answers are grounded in this paper and cite their sources.
Pharmacokinetic analysis demonstrates glecaprevir-pibrentasvir levels in breast milk among lactating women, indicating pathways to expand hepatitis C cure access.
Women living with hepatitis C (HCV) must often choose between breastfeeding or accessing HCV cure. The analysis reported by McCrary et al. on the pharmacokinetics of glecaprevir-pibrentasvir (GLE/PIB) in breast milk lays important groundwork to support future studies informing safety.
No takes yet. Share an insight, caveat, or question.
Audrey R. Lloyd (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: